Oli is a senior associate in our Cambridge office and is part of the Corporate Technology team.
Oli advises a range of companies in the tech and life sciences sectors on a variety of corporate matters, including venture capital investments, fundraisings, M&A and joint ventures.
Advising on Draig Therapeutics' US$140 million series A financing
We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.
Advised Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases based in Cambridge UK, on its $47 million Series C funding. The funding was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest venture capital firms, with participation from new and existing investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners.
Apollo Therapeutics closes $226.5 million series C financing
We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Advising Biomodal (formerly Cambridge Epigenetix) on its US$88 million Series D funding round to advance best-in-class DNA sequencing technology platform
